Trial Profile
A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Encequidar+paclitaxel-Athenex (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Athenex
- 27 Apr 2019 Status changed from recruiting to completed.
- 05 Jun 2018 Interim results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2018 According to an Athenex media release, data will be presented at the American Society of Clinical Oncology (ASCO) Meeting 2018.